Sentences with phrase «in immunotherapy at»

The introduction of CRISPR, which is simpler and more efficient than other techniques, will probably accelerate the race to get gene - edited cells into the clinic across the world, says Carl June, who specializes in immunotherapy at the University of Pennsylvania in Philadelphia and led one of the earlier studies.

«It will be much more powerful than the antibodies,» says Timothy Chan, who does clinical research in immunotherapy at Memorial Sloan Kettering Cancer Center in New York City.

June, a professor in immunotherapy at the University of Pennsylvania, described recent triumphs in cancer research that have now been used to treat more than 300 children with leukemia, all of whom remain in remission.

Not exact matches

His family history is part of the connect - the - dots Parker plays without end, reading late into the night, swimming in medical papers, diving into conversations with researchers of any stripe — discussing malarial vectors with Sir Richard Feachem at UCSF and checkpoint inhibitors with Jim Allison, a groundbreaking immunotherapy researcher at MD Anderson in Houston.

In the most recent of these reports (in the latest issue of Science), Dr. Jennifer Wargo, a surgeon and research scientist at M.D. Anderson, along with several dozen colleagues at other institutions, reveal that the composition of a patient's gut microbiota can significantly influence whether he or she responds to an immune checkpoint inhibitor — the type of cancer immunotherapy that releases the emergency brakes in the car analogy abovIn the most recent of these reports (in the latest issue of Science), Dr. Jennifer Wargo, a surgeon and research scientist at M.D. Anderson, along with several dozen colleagues at other institutions, reveal that the composition of a patient's gut microbiota can significantly influence whether he or she responds to an immune checkpoint inhibitor — the type of cancer immunotherapy that releases the emergency brakes in the car analogy abovin the latest issue of Science), Dr. Jennifer Wargo, a surgeon and research scientist at M.D. Anderson, along with several dozen colleagues at other institutions, reveal that the composition of a patient's gut microbiota can significantly influence whether he or she responds to an immune checkpoint inhibitor — the type of cancer immunotherapy that releases the emergency brakes in the car analogy abovin the car analogy above.

And when Ziskin's breast cancer had reemerged with brutal efficiency after a long remission, Parker had managed to get her into a last - ditch immunotherapy protocol at the Hutch, the famed Fred Hutchinson Cancer Research Center in Seattle — chartering private planes at his own expense to shepherd her back and forth from Los Angeles.

Dr. Peter Kiener has substantial experience in both biologics and immunotherapy, and was most recently the Chief Scientific Officer at Sucampo, which was acquired by Mallinckrodt in February 2018 for approximately $ 1.2 billion.

«We have decided not to move forward with the ROCKET trial or JCAR015 at this time, even though it generated important learnings for us and the immunotherapy field,» Juno president and CEO Hans Bishop said yesterday in a statement.

The company's CAR T - cell cancer immunotherapy furthest in development at present is JCAR017.

Now, immunotherapy is at the forefront in oncology as a leading therapeutic which has been shown to cure cancer in previously untreatable patients.

Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

Doug Mahoney's lab at the University of Calgary recently discovered an immunotherapy that uses existing cancer drugs in a whole new way.

His lab is one of three in the world looking at this immunotherapy combination.

After completing his Ph.D. in 2002 and staying on at ICL for a 2 - year postdoc, Barroso took a senior scientist position in cancer immunotherapy at GSK.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

Immunotherapy doubles overall survival and improves quality of life, with fewer side effects, in a treatment - resistant and rapidly progressing form of head and neck carcinoma, reports a large, randomized international trial co-led by investigators at the University of Pittsburgh Cancer Institute (UPCI).

My next career step was to accept a 6 - month position, which was then extended by an additional year, to establish a translational research laboratory for cancer immunotherapy at the Gustave Roussy Cancer Campus, a major nonprofit health care, research, and teaching institution in Paris.

Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90 % disease control and 59 % response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

Allison, chair of the immunology department at the University of Texas M.D. Anderson Cancer Center in Houston and executive director of its research center on immunotherapy, spoke with Scientific American about the future prospects and limitations of immunotherapy.

Biden has also been talking to Los Angeles, California, oncologist and billionaire Patrick Soon - Shiong, who on 11 January announced an industry - led moonshot aimed at testing in clinical trials combinations of cancer immunotherapy drugs, one of most promising new cancer treatments in recent years.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

«Dendritic cells are essential for prompting the immune response against malignant cells and for driving the clinical success of cancer immunotherapy, but their function is often defective in cancer patients,» said Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and program leader of the Immunology, Microenvironment & Metastasis Program at Wistar.

The approach to immunotherapy embodied in nivolumab is a legacy of work at Dana - Farber that began in the 1980s.

In his day job, at the University of Texas MD Anderson Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortalitIn his day job, at the University of Texas MD Anderson Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortalitin Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortality.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strategy.

In this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodieIn this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodiein 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodies.

In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification.

While a postdoctoral fellow at the Naval Medical Research Institute in Bethesda, he developed a system for large - scale efficient culture of lymphocytes that has proved to be the foundation for over 35 early phase clinical trials of adoptive immunotherapy.

Dr. Cooper joined MDACC in 2006 as section chief of cell therapy at the Children's Cancer Hospital, where he cared for children undergoing bone marrow transplantation and led scientific efforts to develop new treatment approaches that pair genetic engineering with immunotherapies.

Following a postdoctoral fellowship at Memorial Sloan - Kettering Cancer Center (MSKCC) in New York, he joined the Ludwig Institute for Cancer Research at MSKCC, where he eventually became an associate member and was named director of Immunological Monitoring at the Ludwig Center for Cancer Immunotherapy.

«Recent successes in cancer immunotherapy — in the form of immune checkpoint inhibitors and adoptive T cell transfer — demonstrate how activated immune cells can eradicate tumors, but until now we didn't fully appreciate immunosurveillance or the role of adaptive immunity in tumor formation,» said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at UC San Diego School of Medicine.

The results of the study were published this week in the journal Nature Medicine from researchers at Penn's Abramson Cancer Center, including senior author Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the ACC, the University of Maryland School of Medicine, and Adaptimmune Therapeutics plc (Adaptimmune).

The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.

«This new class of immunotherapy drug traps white blood cells in the lymph nodes to prevent their escape into the gut where they cause inflammation,» said William J. Sandborn, MD, professor of medicine at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

On 29 September, AAAS hosted a lively online discussion on Reddit's «Ask Me Anything» (AMA) forum on implicit bias in science — a discussion Smith joined, along with Shirley Malcom, AAAS» director of Education and Human Resources programs, Caleph B. Wilson, a biomedical scientist with Cellectis, a biopharmaceutical company, and Avery Posey, Jr., an instructor in the Center for Cellular Immunotherapies at the Perelman School of Medicine at the University of Pennsylvania.

«Checkpoint inhibitors are one of the most exciting recent advances for cancers, but the mechanism by which most patients become resistant to these therapies has been a mystery,» says Victor E. Velculescu, M.D., Ph.D., program leader in the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and professor of oncology.

Melanoma patients» response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO - Society for Immunotherapy in Cancer meetinimmunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO - Society for Immunotherapy in Cancer meetinImmunotherapy in Cancer meeting in Orlando.

While the finding does not directly lead to a test for immunotherapy response yet, Choueiri said, «We intend to look at these specific genomic alterations in larger, randomized controlled trials, and we hope that one day these findings will be the impetus for prospective clinical trials based on these alterations.»

«It's essentially what all of us have been striving for in immunotherapy,» says James Mulé, an immunologist at the University of Michigan Medical School in Ann Arbor.

«Everybody out there working in the cancer space is trying to figure out ways to enhance checkpoint blockade immunotherapy,» said Wenbin Lin, James Franck Professor in Chemistry at UChicago and one of the scientists who conceived the new therapy.

«We wanted to look at the patients» tumor and immune system prior to treatment and examine it again after treatment for changes,» said Patrick Forde, first author and co-principle investigator of the trial and a lung cancer oncologist in the Bloomberg ~ Kimmel Institute of Cancer Immunotherapy.

In their report published in Cancer Immunology Research, a team from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) describes how adding AMD3100 (plerixafor)-- previously approved for the stimulation of stem cell production prior to bone marrow transplantation — to their investigational drug VIC - 008 more than doubled the animals» survival timIn their report published in Cancer Immunology Research, a team from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) describes how adding AMD3100 (plerixafor)-- previously approved for the stimulation of stem cell production prior to bone marrow transplantation — to their investigational drug VIC - 008 more than doubled the animals» survival timin Cancer Immunology Research, a team from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) describes how adding AMD3100 (plerixafor)-- previously approved for the stimulation of stem cell production prior to bone marrow transplantation — to their investigational drug VIC - 008 more than doubled the animals» survival time.

Wherry, together with his colleagues in the Parker Institute for Cancer Immunotherapy at Penn, are involved in multiple checkpoint - related trials, in melanoma, lung cancer, renal cell carcinoma, and others, including combining checkpoint blockade with radiation.

«The field of immunotherapy has exploded in the last decade, and more and more patients are benefiting,» said press briefing moderator Steven O'Day, MD, ASCO expert and clinical associate professor of medicine at the University of Southern California, Keck School of Medicine.

In 2010, she enrolled in a clinical trial of a new immunotherapy drug, called nivolumab, being tested at Moffitt Cancer Center in Florida under the direction of Jeffrey S. Weber, M.D., Ph.DIn 2010, she enrolled in a clinical trial of a new immunotherapy drug, called nivolumab, being tested at Moffitt Cancer Center in Florida under the direction of Jeffrey S. Weber, M.D., Ph.Din a clinical trial of a new immunotherapy drug, called nivolumab, being tested at Moffitt Cancer Center in Florida under the direction of Jeffrey S. Weber, M.D., Ph.Din Florida under the direction of Jeffrey S. Weber, M.D., Ph.D..

Dr. Jennifer S. Temel, clinical director of thoracic oncology at Massachusetts General Hospital, alluded to the emerging research on immunotherapy in a presentation to palliative care and hospice clinicians in February.

NEW YORK, August 29, 2016 — The Cancer Research Institute (CRI), a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced today that it will honor biotechnology company Amgen with the 2016 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research at its September gala in New York City.

The FDA granted approval to a new, first - in - class immunotherapy — tisagenlecleucel (Kymriah, Novartis)-- for the treatment patients up to 25 years old with B cell acute lymphoblastic leukemia (B - ALL) that is refractory or has relapsed after at least two previous treatments.